| Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial.Nat Commun | PMID 39261482PMC11390939 | 2024-Sep-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.J Clin Oncol | PMID 39018515PMC11379357 | 2024-Sep-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome.J Am Coll Cardiol | PMID 39232634无 PMCID | 2024-Sep-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis.Acta Derm Venereol | PMID 39248292PMC11403364 | 2024-Sep-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of fentanyl inhalant for the treatment of breakthrough cancer pain: a multicenter, randomized, double-blind, placebo-controlled trial.BMC Palliat Care | PMID 39244530PMC11380773 | 2024-Sep-07 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).Arthritis Res Ther | PMID 39244595PMC11380339 | 2024-Sep-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.Oncologist | PMID 38748596PMC11379636 | 2024-Sep-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial.Neuro Oncol | PMID 38502052PMC11376448 | 2024-Sep-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.Blood | PMID 38754046PMC11406168 | 2024-Sep-05 | 0.85 | This is a descriptive analysis of mutational profiles and clonal evolution in patients with CLL progression on BTK inhibitors. It is not a report of a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, KM, HR). | 待处理 |
| Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.N Engl J Med | PMID 39231341无 PMCID | 2024-Sep-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.N Engl J Med | PMID 39231343PMC11528349 | 2024-Sep-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial.Acta Derm Venereol | PMID 39233617PMC11388105 | 2024-Sep-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections.Antimicrob Agents Chemother | PMID 39082883PMC11373226 | 2024-Sep-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quantitative comparison of automated OCT and conventional FAF-based geographic atrophy measurements in the phase 3 OAKS/DERBY trials.Sci Rep | PMID 39227682PMC11372055 | 2024-Sep-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Exercise and QUality Diet after Leukemia: A Randomized Weight Loss Trial among Adult Survivors of Childhood Leukemia in the Childhood Cancer Survivor Study.Cancer Epidemiol Biomarkers Prev | PMID 38652494PMC11371536 | 2024-Sep-03 | 0.95 | The study is an oncology randomized trial with original results, but it does not meet the required criteria: the primary endpoint is weight change (a continuous measure), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). Additionally, the intervention is a behavioral/lifestyle program (exercise and diet), not a drug-containing intervention. | 待处理 |
| Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis.RMD Open | PMID 39231546PMC11409351 | 2024-Sep-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Iloprost and Organ Dysfunction in Adults With Septic Shock and Endotheliopathy: A Randomized Clinical Trial.JAMA Netw Open | PMID 39259541PMC11391323 | 2024-Sep-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study.Cornea | PMID 37921522PMC11296276 | 2024-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.J Clin Gastroenterol | PMID 38019088PMC11305620 | 2024-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial.J Clin Oncol | PMID 38564700无 PMCID | 2024-Sep-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies.Rheumatology (Oxford) | PMID 38754125PMC11371372 | 2024-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.J Clin Oncol | PMID 38833643PMC11565489 | 2024-Sep-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.Endocr Relat Cancer | PMID 38913539PMC11301421 | 2024-Sep-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.JAMA Cardiol | PMID 38958989PMC11223044 | 2024-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.J Clin Oncol | PMID 38996201无 PMCID | 2024-Sep-01 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.JAMA Dermatol | PMID 39083288PMC11292573 | 2024-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Post Hoc Analysis Comparing the Safety and Efficacy of PrabotulinumtoxinA in Millennials and Nonmillennials With Moderate to Severe Glabellar Lines.Dermatol Surg | PMID 39196832无 PMCID | 2024-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomized Clinical Trial.Asian Pac J Cancer Prev | PMID 39342581PMC11700305 | 2024-Sep-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.Clin J Am Soc Nephrol | PMID 40179340PMC11390031 | 2024-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus.J Diabetes Investig | PMID 38794986PMC11363113 | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial.Diabetes Metab J | PMID 38310875PMC11449822 | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The hepatocyte growth factor mimetic, ANG-3777, in kidney transplant recipients with delayed graft function: Results from a randomized phase 3 trial.Am J Transplant | PMID 38387622无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized controlled trial of remimazolam compared with placebo in Japanese patients undergoing upper gastrointestinal endoscopy: Phase III investigator-initiated clinical trial.Dig Endosc | PMID 38403959无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study.Ophthalmology | PMID 38423215无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension.Ophthalmology | PMID 38423216无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.Prostate Cancer Prostatic Dis | PMID 38424319PMC12036820 | 2024-Sep | 0.85 | This is a pre-planned subset analysis of a Phase III randomized trial, not the primary or key secondary efficacy report of the trial itself. While it reports on OS, the focus is on biomarker prognostic value within a subset, not the primary comparison of drug interventions. | 待处理 |
| Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment.Eur J Intern Med | PMID 38521730无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.J Formos Med Assoc | PMID 38548524无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparing the latent state-trait structure of the PANSS in cariprazine-medicated and placebo-controlled patients with acute schizophrenia.Eur Arch Psychiatry Clin Neurosci | PMID 38553640PMC11362189 | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Model-Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate-to-Severe Ulcerative Colitis.Clin Pharmacol Ther | PMID 38627914无 PMCID | 2024-Sep | 0.85 | The record describes a non-oncology disease (ulcerative colitis), reports on a Phase 2b trial used to model predictions for a future Phase 3 study, and does not report any time-to-event efficacy endpoints (Kaplan-Meier or HR). | 待处理 |
| Pharmacokinetics of Edoxaban 15 mg in Very Elderly Patients with Nonvalvular Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Study.Thromb Haemost | PMID 38641335PMC11349424 | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis.J Am Acad Dermatol | PMID 38685404无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.Ann Allergy Asthma Immunol | PMID 38697286无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study.J Allergy Clin Immunol Pract | PMID 38777124无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.J Am Acad Dermatol | PMID 38777187无 PMCID | 2024-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.Eur J Nucl Med Mol Imaging | PMID 38795120无 PMCID | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS.J Manag Care Spec Pharm | PMID 38807035PMC11365817 | 2024-Sep | 0.95 | The record describes a Phase III randomized trial of darolutamide in mHSPC with drug intervention, but the analysis is a health-economic and resource utilization study focusing on hospitalization rates and budget impact. It does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curve, or HR) required for inclusion in the oncology Kaplan-Meier digitization cohort. | 待处理 |
| Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.Eur Urol | PMID 38811313PMC12036081 | 2024-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.Nat Med | PMID 38823511PMC11405267 | 2024-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center.JCO Oncol Pract | PMID 38848539无 PMCID | 2024-Sep | 0.85 | The study is an implementation science trial focused on medication safety with oral antitumor therapy. While it is an oncology, human, randomized, Phase III trial with a drug intervention and reports original results, it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). Its primary endpoint is an implementation outcome (percentage of patients counseled). | 待处理 |